Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Wayne Yeh, M.D.

Co-Author

This page shows the publications co-authored by Robert Yeh and Eric Secemsky.
Connection Strength

23.715
  1. Long-term safety of drug-coated devices for peripheral revascularisation. EuroIntervention. 2021 Sep 20; 17(7):590-598.
    View in: PubMed
    Score: 0.960
  2. Comparative Outcomes of Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction Among Medicare Beneficiaries With Multivessel Coronary Artery Disease: An National Cardiovascular Data Registry Research to Practice Project. Circ Cardiovasc Interv. 2021 08; 14(8):e010323.
    View in: PubMed
    Score: 0.952
  3. Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study. JAMA Intern Med. 2021 08 01; 181(8):1071-1080.
    View in: PubMed
    Score: 0.951
  4. Temporal Changes and Institutional Variation in Use of Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction With Multivessel Coronary Artery Disease in the United States: An NCDR Research to Practice Project. JAMA Cardiol. 2021 05 01; 6(5):574-580.
    View in: PubMed
    Score: 0.934
  5. Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices. JAMA Cardiol. 2019 04 01; 4(4):332-340.
    View in: PubMed
    Score: 0.809
  6. Drug-Eluting Stent Implantation and Long-Term Survival Following Peripheral Artery Revascularization. J Am Coll Cardiol. 2019 05 28; 73(20):2636-2638.
    View in: PubMed
    Score: 0.804
  7. Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: The National Cardiovascular Data Registry CathPCI Registry. JAMA Cardiol. 2019 02 01; 4(2):110-118.
    View in: PubMed
    Score: 0.800
  8. Re: Multivessel Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction with Cardiogenic Shock. Epidemiology. 2018 11; 29(6):e59-e60.
    View in: PubMed
    Score: 0.786
  9. Inferior Vena Cava Filters and Mortality: Is It the Underlying Process, the Patient, or the Device? JAMA Netw Open. 2018 07 06; 1(3):e180453.
    View in: PubMed
    Score: 0.768
  10. Exposure Misclassification in Observational Studies: Setting New Standards. Circ Cardiovasc Qual Outcomes. 2018 07; 11(7):e004939.
    View in: PubMed
    Score: 0.768
  11. High Burden of 30-Day Readmissions After Acute Venous Thromboembolism in the United States. J Am Heart Assoc. 2018 06 26; 7(13).
    View in: PubMed
    Score: 0.767
  12. Complete vs Incomplete Revascularization During Percutaneous Coronary Intervention and Improved Survival-The Key Is Immortality. JAMA Cardiol. 2018 05 01; 3(5):443-444.
    View in: PubMed
    Score: 0.759
  13. Readmissions After Revascularization Procedures for Peripheral Arterial Disease: A Nationwide Cohort Study. Ann Intern Med. 2018 01 16; 168(2):93-99.
    View in: PubMed
    Score: 0.738
  14. Brachial-ankle pulse wave velocity as a marker of adverse events following non-ST-elevation myocardial infarction: a new standard in risk stratification? Coron Artery Dis. 2017 12; 28(8):634-635.
    View in: PubMed
    Score: 0.737
  15. Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States. Circ Cardiovasc Qual Outcomes. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.725
  16. Target Vessel Revascularization and Territory of Myocardial Ischemia in Patients With Chronic Total Occlusions. J Am Coll Cardiol. 2017 08 29; 70(9):1196-1197.
    View in: PubMed
    Score: 0.724
  17. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. JACC Cardiovasc Interv. 2016 12 12; 9(23):2376-2386.
    View in: PubMed
    Score: 0.685
  18. Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2016 10 17; 5(10).
    View in: PubMed
    Score: 0.682
  19. Letter by Secemsky et al Regarding Article, "Relationship Between Femoral Vascular Closure Devices and Short-Term Mortality From 271?845 Percutaneous Coronary Intervention Procedures Performed in the United Kingdom Between 2006 and 2011: A Propensity Score-Corrected Analysis From the British Cardiovascular Intervention Society". Circ Cardiovasc Interv. 2016 09; 9(9).
    View in: PubMed
    Score: 0.676
  20. Outcomes Associated With Peripheral Artery Disease in Myocardial Infarction With Cardiogenic Shock. J Am Coll Cardiol. 2022 Apr 05; 79(13):1223-1235.
    View in: PubMed
    Score: 0.249
  21. Accuracy of Administrative Claims Codes for Identifying Devices Used in Endovascular Femoropopliteal Artery Revascularisation: A Retrospective Observational Study at Two Tertiary Centres in the United States. Eur J Vasc Endovasc Surg. 2022 Mar 17.
    View in: PubMed
    Score: 0.248
  22. Individualizing dual antiplatelet therapy (DAPT) duration based on bleeding risk, ischemic risk, or both: An analysis from the DAPT Study. Cardiovasc Revasc Med. 2022 Jan 12.
    View in: PubMed
    Score: 0.245
  23. Association of Frailty With Treatment Selection and Long-Term Outcomes Among Patients With Chronic Limb-Threatening Ischemia. J Am Heart Assoc. 2021 12 21; 10(24):e023138.
    View in: PubMed
    Score: 0.244
  24. Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. Circulation. 2022 01 11; 145(2):97-106.
    View in: PubMed
    Score: 0.242
  25. Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice: Findings From EXTEND-CoreValve. JACC Cardiovasc Interv. 2021 10 11; 14(19):2112-2123.
    View in: PubMed
    Score: 0.241
  26. Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. EuroIntervention. 2021 Aug 06; 17(5):e380-e387.
    View in: PubMed
    Score: 0.238
  27. Comparing Baseline Data From Registries With Trials: Evidence From the CathPCI Registry and DAPT Study. JACC Cardiovasc Interv. 2021 06 28; 14(12):1386-1388.
    View in: PubMed
    Score: 0.236
  28. New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries [NCDR] Linked With All-Payer Claims). Am J Cardiol. 2021 07 15; 151:70-77.
    View in: PubMed
    Score: 0.235
  29. Prognosis of Claims- Versus Trial-Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. J Am Heart Assoc. 2021 03 16; 10(6):e018744.
    View in: PubMed
    Score: 0.231
  30. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study: Findings From the EXTEND-DAPT Study. Circ Cardiovasc Qual Outcomes. 2021 01; 14(1):e006589.
    View in: PubMed
    Score: 0.229
  31. Rationale and Design of the SAFE-PAD Study. Circ Cardiovasc Qual Outcomes. 2021 01; 14(1):e007040.
    View in: PubMed
    Score: 0.229
  32. Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis. J Endovasc Ther. 2021 Apr; 28(2):246-254.
    View in: PubMed
    Score: 0.229
  33. Assessing health-related quality of life among patients with peripheral artery disease: A review of the literature and focus on patient-reported outcome measures. Vasc Med. 2021 06; 26(3):317-325.
    View in: PubMed
    Score: 0.227
  34. Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2021 03; 97(4):569-578.
    View in: PubMed
    Score: 0.225
  35. Revascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. JAMA Intern Med. 2020 10 01; 180(10):1317-1327.
    View in: PubMed
    Score: 0.224
  36. Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. Circulation. 2020 07 21; 142(3):306-308.
    View in: PubMed
    Score: 0.221
  37. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative. Circ Cardiovasc Qual Outcomes. 2020 03; 13(3):e006275.
    View in: PubMed
    Score: 0.216
  38. Readmissions after acute type B aortic dissection. J Vasc Surg. 2020 07; 72(1):73-83.e2.
    View in: PubMed
    Score: 0.212
  39. Examining the Operator Learning Curve for Percutaneous Coronary Intervention of Chronic Total Occlusions. Circ Cardiovasc Interv. 2019 08; 12(8):e007877.
    View in: PubMed
    Score: 0.207
  40. Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. Coron Artery Dis. 2019 05; 30(3):177-182.
    View in: PubMed
    Score: 0.203
  41. Patient Readmission Rates For All Insurance Types After Implementation Of The Hospital Readmissions Reduction Program. Health Aff (Millwood). 2019 04; 38(4):585-593.
    View in: PubMed
    Score: 0.202
  42. Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention: The OPEN-CTO Registry. JACC Cardiovasc Interv. 2019 04 08; 12(7):651-658.
    View in: PubMed
    Score: 0.201
  43. Temporal Trends in Unstable Angina Diagnosis Codes for Outpatient Percutaneous Coronary Interventions. JAMA Intern Med. 2019 02 01; 179(2):259-261.
    View in: PubMed
    Score: 0.200
  44. The DAPT Score in Sweden: Successful Validation, Flawed Interpretation. J Am Coll Cardiol. 2019 01 08; 73(1):113-114.
    View in: PubMed
    Score: 0.199
  45. Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. BMJ. 2018 Dec 13; 363:k5094.
    View in: PubMed
    Score: 0.198
  46. Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy. PLoS One. 2018; 13(10):e0205457.
    View in: PubMed
    Score: 0.196
  47. State Variation in the Use of Non-Acute Coronary Angiograms and Coronary Revascularization Procedures. JACC Cardiovasc Interv. 2018 05 14; 11(9):912-913.
    View in: PubMed
    Score: 0.190
  48. Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician. Prog Cardiovasc Dis. 2018 Jan - Feb; 60(4-5):491-499.
    View in: PubMed
    Score: 0.187
  49. Seasonality and Readmission after Heart Failure, Myocardial Infarction, and Pneumonia. Health Serv Res. 2018 08; 53(4):2185-2202.
    View in: PubMed
    Score: 0.181
  50. Reply: Duration of the Double Antiplatelet Therapy in Patients With Coronary and Peripheral Arterial Disease: The Key Might Be in the Type of Drug. JACC Cardiovasc Interv. 2017 07 24; 10(14):1468-1469.
    View in: PubMed
    Score: 0.180
  51. Comparison of 30-Day Readmission Rates After Hospitalization for Acute Myocardial Infarction in Men Versus Women. Am J Cardiol. 2017 Oct 01; 120(7):1070-1076.
    View in: PubMed
    Score: 0.179
  52. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC Cardiovasc Interv. 2017 05 08; 10(9):942-954.
    View in: PubMed
    Score: 0.177
  53. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol. 2017 05 01; 2(5):478-487.
    View in: PubMed
    Score: 0.177
  54. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26; 315(16):1735-49.
    View in: PubMed
    Score: 0.165
  55. Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention: An Instrumental Variable Analysis. Circ Cardiovasc Interv. 2016 Apr; 9(4):e003464.
    View in: PubMed
    Score: 0.164
  56. Response to Letter Regarding Article, "Surgical Ineligibility and Mortality Among Patients With Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention". Circulation. 2015 Sep 22; 132(12):e156.
    View in: PubMed
    Score: 0.158
  57. Public reporting in cardiovascular medicine: accountability, unintended consequences, and promise for improvement. Circulation. 2015 Apr 28; 131(17):1518-27.
    View in: PubMed
    Score: 0.154
  58. Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials). Am J Cardiol. 2015 Jun 15; 115(12):1678-84.
    View in: PubMed
    Score: 0.153
  59. Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2014 Dec 23; 130(25):2295-301.
    View in: PubMed
    Score: 0.149
  60. Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Coll Cardiol. 2021 11 02; 78(18):1768-1778.
    View in: PubMed
    Score: 0.060
  61. National trends in utilization of thrombolytic therapy for acute pulmonary embolism. Vasc Med. 2022 02; 27(1):75-76.
    View in: PubMed
    Score: 0.060
  62. Association of Socioeconomic Disadvantage With Mortality and Readmissions Among Older Adults Hospitalized for Pulmonary Embolism in the United States. J Am Heart Assoc. 2021 07 06; 10(13):e021117.
    View in: PubMed
    Score: 0.059
  63. Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection. Eur Heart J Qual Care Clin Outcomes. 2021 05 03; 7(3):273-279.
    View in: PubMed
    Score: 0.058
  64. Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve Therapy Registry. Circulation. 2021 06 08; 143(23):2229-2240.
    View in: PubMed
    Score: 0.058
  65. Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement: Variation in Practice and Outcomes. JACC Cardiovasc Interv. 2020 06 08; 13(11):1277-1287.
    View in: PubMed
    Score: 0.055
  66. Utilization and Outcomes of Thrombolytic Therapy for Acute Pulmonary Embolism: A Nationwide Cohort Study. Chest. 2020 03; 157(3):645-653.
    View in: PubMed
    Score: 0.053
  67. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2017 06 12; 10(11):1102-1111.
    View in: PubMed
    Score: 0.044
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.